Emerging New Concepts of Degrader Technologies
Yu Ding,Yiyan Fei,Boxun Lu
DOI: https://doi.org/10.1016/j.tips.2020.04.005
IF: 17.638
2020-01-01
Trends in Pharmacological Sciences
Abstract:Selective degradation of pathogenic proteins is a promising strategy to drug 'undruggable' targets.Established degrader technologies such as PROTAC are extremely promising but still have limitations.The lysosome is a major degradation pathway utilized by cells to degrade extracellular and intracellular content.New technologies such as LYTAC, AUTAC, and ATTEC may have potential applications in several diseases by exploiting the lysosome for targeted degradation. Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This typically relies on a measurable biochemical readout and accessible binding sites whose occupancy influences the function of the target protein. These requirements preclude many disease-causing proteins from being 'druggable' targets, and these proteins are categorized as 'undruggable'. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these undruggable targets and has become a promising approach for drug discovery. However, the PROTAC technology has some limitations, and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing a second major degradation pathway in cells. We review key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications and limitations. Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This typically relies on a measurable biochemical readout and accessible binding sites whose occupancy influences the function of the target protein. These requirements preclude many disease-causing proteins from being 'druggable' targets, and these proteins are categorized as 'undruggable'. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these undruggable targets and has become a promising approach for drug discovery. However, the PROTAC technology has some limitations, and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing a second major degradation pathway in cells. We review key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications and limitations. Human genetic studies have revealed a large number of novel protein targets that cause disease via toxic gain of function. The abnormal accumulation and toxicity of these pathogenic proteins may directly cause many diseases including neurodegenerative disorders and type 2 diabetes [1.Walker L.C. LeVine H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly.Mol. Neurobiol. 2000; 21: 83-95Crossref PubMed Google Scholar,2.Chiti F. Dobson C.M. Protein misfolding, functional amyloid, and human disease.Annu. Rev. Biochem. 2006; 75: 333-366Crossref PubMed Scopus (5396) Google Scholar]. Traditional inhibitor identification-based drug discovery strategies are limited by the requirements of specific measurable functions of the target protein and accessible binding sites whose occupancy directly influences their function. Because of these requirements, almost all the disease-relevant scaffolding proteins, transcription factors, and other non-enzymatic proteins are essentially undruggable by the inhibitor approach. One appealing idea to address this is to enhance the global protein quality control system such that these undruggable pathogenic proteins can be corrected or eliminated. For example, remodeling the proteostasis network by small molecules targeting molecular chaperones or inducing stress responses may reduce the aggregation and toxicity of multiple disease-linked proteins in animal models (reviewed in [3.Sala A.J. et al.Shaping proteostasis at the cellular, tissue, and organismal level.J. Cell Biol. 2017; 216: 1231-1241Crossref PubMed Scopus (163) Google Scholar]). Furthermore, the induction of autophagy may provide a potential therapeutic strategy for many neurodegenerative diseases that are possibly caused by pathogenic proteins (reviewed in [4.Djajadikerta A. et al.Autophagy induction as a therapeutic strategy for neurodegenerative diseases.J. Mol. Biol. 2019; (Published online December 27, 2019. http://dx.doi.org/j.jmb.2019.1012.1035)PubMed Google Scholar]). Although these approaches have potential in treating multiple diseases, they induce global cellular changes and thus may have extensive nonspecific effects or induce strong compensatory mechanisms that offset their beneficial effects. A more specific strategy would be to selectively reduce the levels of the pathogenic proteins. One possible approach is gene therapy: gene silencing through nucleic acid-based RNA- or DNA-targeting reagents such as antisense oligonucleotides (ASOs) and genome-editing reagents, respectively [5.Schoch K.M. Miller T.M. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases.Neuron. 2017; 94: 1056-1070Abstract Full Text Full Text PDF PubMed Scopus (205) Google Scholar,6.Maeder M.L. Gersbach C.A. Genome-editing technologies for gene and cell therapy.Mol. Ther. 2016; 24: 430-446Abstract Full Text Full Text PDF PubMed Scopus (465) Google Scholar] (Figure 1A ). Although highly promising, this approach faces some key challenges. Because they are large biomolecules, the gene therapy reagents are difficult to deliver, especially for neurological disease [7.Evers M.M. et al.Antisense oligonucleotides in therapy for neurodegenerative disorders.Adv. Drug Deliv. Rev. 2015; 87: 90-103Crossref PubMed Scopus (224) Google Scholar], and they are also prohibitively expensivei. Small molecule-induced protein degradation is an attractive alternative approach to selectively reduce the levels of pathogenic proteins, and may fulfill huge unmet medical needs. Several new approaches have been established to achieve this goal, as discussed later. Small molecules are able to induce selective degradation of the target protein of interest (POI) by adding a tag that is recognized by the degradation machinery. In 2011–2012, Crews and colleagues reported small-molecule hydrophobic tagging (HyT)-induced degradation of POIs [8.Neklesa T.K. et al.Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins.Nat. Chem. Biol. 2011; 7: 538-543Crossref PubMed Scopus (279) Google Scholar,9.Tae H.S. et al.Identification of hydrophobic tags for the degradation of stabilized proteins.ChemBioChem. 2012; 13: 538-541Crossref PubMed Scopus (66) Google Scholar]. HyT was achieved by molecules consisting of a hydrophobic fragment and a ligand binding to the POI. Thus, the HyT molecules bind to the POI and add a hydrophobic fragment to it, leading to recognition and recruitment of heat-shock proteins followed by proteasomal degradation [8.Neklesa T.K. et al.Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins.Nat. Chem. Biol. 2011; 7: 538-543Crossref PubMed Scopus (279) Google Scholar,9.Tae H.S. et al.Identification of hydrophobic tags for the degradation of stabilized proteins.ChemBioChem. 2012; 13: 538-541Crossref PubMed Scopus (66) Google Scholar]. A similar concept was illustrated by another study that used a small molecule consisting of a hydrophobic group tert-butyl carbamate-protected arginine (Boc3Arg) attached to the dihydrofolate reductase (DHFR) non-covalent binding ligand trimethoprim (TMP) to degrade DHFR [10.Long M.J. et al.Inhibitor mediated protein degradation.Chem. Biol. 2012; 19: 629-637Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar]. The Boc3Arg-TMP molecules may recycle during the degradation process, increasing its efficacy [10.Long M.J. et al.Inhibitor mediated protein degradation.Chem. Biol. 2012; 19: 629-637Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar]. Hedstrom and colleagues synthesized chimeric molecules by linking other POI recognition ligands to Boc3Arg and also found that they can target POIs to the 20S proteasome for degradation directly without the requirement for ATP or involvement of ubiquitination pathways [11.Shi Y. et al.Boc3Arg-linked ligands induce degradation by localizing target proteins to the 20S proteasome.ACS Chem. Biol. 2016; 11: 3328-3337Crossref PubMed Scopus (49) Google Scholar] (Figure 1). Although HyT is an interesting concept, it has not been widely used and its clinical application may be limited by Boc3Arg off-target effects [12.Coffey R.T. et al.Ubiquilin-mediated small molecule inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling.J. Biol. Chem. 2016; 291: 5221-5233Crossref PubMed Scopus (27) Google Scholar]. Currently, the prevailing approach for small molecule-induced protein degradation is the proteolysis-targeting chimera (PROTAC) technology, which provides a powerful strategy to degrade undruggable POIs and has been extensively reviewed [13.Konstantinidou M. et al.PROTACs – a game-changing technology.Expert Opin. Drug Discovery. 2019; 14: 1255-1268Crossref PubMed Scopus (107) Google Scholar, 14.Schapira M. et al.Targeted protein degradation: expanding the toolbox.Nat. Rev. Drug Discov. 2019; 18: 949-963Crossref PubMed Scopus (472) Google Scholar, 15.Sun X. et al.PROTACs: great opportunities for academia and industry.Signal Transd. Target. Ther. 2019; 4: 64Crossref PubMed Scopus (373) Google Scholar, 16.Burslem G.M. Crews C.M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery.Cell. 2020; 181: 102-114Abstract Full Text Full Text PDF PubMed Scopus (517) Google Scholar, 17.Wang Y. et al.Degradation of proteins by PROTACs and other strategies.Acta Pharm. Sin. B. 2020; 10: 207-238Crossref PubMed Scopus (185) Google Scholar]. PROTAC molecules tether the POI to a specific E3 ligase subunit to enhance POI ubiquitination, leading to its subsequent degradation by the proteasome (Figure 1). In 2001, Crews and colleagues provided the proof-of-concept evidence for PROTAC [18.Sakamoto K.M. et al.Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation.Proc. Natl. Acad. Sci. 2001; 98: 8554-8559Crossref PubMed Scopus (1366) Google Scholar]. They synthesized a chimeric large molecule named Protac-1 to recruit MetAP-2 to the Skp1–Cullin–F box complex, leading to ubiquitination and degradation of MetAP-2 in a dose-dependent manner. However, the MetAP-2 covalently bound moiety was a peptide, hindering further applications because its large molecule size leads to poor cellular penetration. In 2008, a cell-permeable PROTAC molecule linking the non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand nutlin with a polyethylene glycol (PEG)-based linker was synthesized [19.Schneekloth A.R. et al.Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics.Bioorg. Med. Chem. Lett. 2008; 18: 5904-5908Crossref PubMed Scopus (413) Google Scholar]. This PROTAC molecule can induce the ubiquitination of the androgen receptor and its subsequent degradation by the proteasome. This PROTAC system is based on MDM2, the major E3 ligase that ubiquitinates the tumor-suppressor protein p53 [20.Fuchs S.Y. et al.Mdm2 association with p53 targets its ubiquitination.Oncogene. 1998; 17: 2543-2547Crossref PubMed Scopus (214) Google Scholar]. The nutlins family consists of small molecules that bind to the p53-binding pocket of MDM2 and thus competitively inhibit the interaction between p53 and MDM2 [21.Vassilev L.T. et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science. 2004; 303: 844-848Crossref PubMed Scopus (3964) Google Scholar], inducing possible off-target effects. The nutlins were further improved to RG7112 [22.Vu B. et al.Discovery of RG7112: a small-molecule MDM2 Inhibitor in clinical development.ACS Med. Chem. Lett. 2013; 4: 466-469Crossref PubMed Scopus (267) Google Scholar] and RG7388 [23.Ding Q. et al.Discovery of RG7388, a potent and selective p53–MDM2 inhibitor in clinical development.J. Med. Chem. 2013; 56: 5979-5983Crossref PubMed Scopus (431) Google Scholar] that showed superior potency and selectivity. In 2010, a new PROTAC system using the cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase was established. Hashimoto and colleagues verified that a hybrid molecule coupling the cIAP1 ligand methyl bestatin and a CRABP ligand can induce degradation of CRABP-II in cells via the proteasomal pathway [24.Itoh Y. et al.Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.J. Am. Chem. Soc. 2010; 132: 5820-5826Crossref PubMed Scopus (314) Google Scholar]. In 2015, the group of Brader established another important PROTAC system based on cereblon (CRBN) [25.Winter G.E. et al.Phthalimide conjugation as a strategy for in vivo target protein degradation.Science. 2015; 348: 1376-1381Crossref PubMed Scopus (1141) Google Scholar]. CRBN was initially identified as the primary mediator of the teratogenic activity of thalidomide by Handa and colleagues [26.Ito T. et al.Identification of a primary target of thalidomide teratogenicity.Science. 2010; 327: 1345-1350Crossref PubMed Scopus (1486) Google Scholar]. Immunomodulatory drugs (IMiDs) including thalidomide and its derivatives such as lenalidomide and pomalidomide were later utilized to treat multiple myeloma [27.Chanan-Khan A.A. et al.Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.Blood Cancer J. 2013; 3e143Crossref PubMed Scopus (98) Google Scholar]. These IMiDs were further reported to interact with the CRBN–DNA damage binding protein 1 (DDB1) complex [28.Lopez-Girona A. et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.Leukemia. 2012; 26: 2326-2335Crossref PubMed Scopus (636) Google Scholar]. Shortly thereafter a series of PROTAC molecules consisting of a CRBN-binding IMiD connected to small-molecule ligands for different POIs were designed and their degrader capability was verified [25.Winter G.E. et al.Phthalimide conjugation as a strategy for in vivo target protein degradation.Science. 2015; 348: 1376-1381Crossref PubMed Scopus (1141) Google Scholar,29.Lu J. et al.Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4.Chem. Biol. 2015; 22: 755-763Abstract Full Text Full Text PDF PubMed Scopus (786) Google Scholar,30.Lai A.C. et al.Modular PROTAC design for the degradation of oncogenic BCR–ABL.Angew. Chem. Int. Ed. Engl. 2016; 55: 807-810Crossref PubMed Scopus (450) Google Scholar]. For example, JQ1–penalidomide chimeric compounds can selectively degrade BRD4 protein via CRBN [25.Winter G.E. et al.Phthalimide conjugation as a strategy for in vivo target protein degradation.Science. 2015; 348: 1376-1381Crossref PubMed Scopus (1141) Google Scholar]. Another PROTAC system, the VHL-PROTAC system based on a HIF1-α-derived peptide, was initially introduced in 2004 [31.Schneekloth Jr., J.S. et al.Chemical genetic control of protein levels: selective in vivo targeted degradation.J. Am. Chem. Soc. 2004; 126: 3748-3754Crossref PubMed Scopus (375) Google Scholar]. In 2015, replacement of the VHL-targeting peptide by hydroxyproline-like small molecules significantly improved the affinity and specificity of the VHL-PROTAC system [32.Bondeson D.P. et al.Catalytic in vivo protein knockdown by small-molecule PROTACs.Nat. Chem. Biol. 2015; 11: 611-617Crossref PubMed Scopus (823) Google Scholar], greatly expanding its applications. Currently, although there are >600 known human E3 ligases, the established PROTAC systems rely on fewer than ten, of which the most widely used are CRBN [28.Lopez-Girona A. et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.Leukemia. 2012; 26: 2326-2335Crossref PubMed Scopus (636) Google Scholar], Von Hippel Lindau (VHL) [31.Schneekloth Jr., J.S. et al.Chemical genetic control of protein levels: selective in vivo targeted degradation.J. Am. Chem. Soc. 2004; 126: 3748-3754Crossref PubMed Scopus (375) Google Scholar], cIAP [24.Itoh Y. et al.Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.J. Am. Chem. Soc. 2010; 132: 5820-5826Crossref PubMed Scopus (314) Google Scholar], and MDM2 [19.Schneekloth A.R. et al.Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics.Bioorg. Med. Chem. Lett. 2008; 18: 5904-5908Crossref PubMed Scopus (413) Google Scholar], discussed earlier. One desirable property of PROTACs is that they are catalytically involved in multiple rounds of target protein degradation [29.Lu J. et al.Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4.Chem. Biol. 2015; 22: 755-763Abstract Full Text Full Text PDF PubMed Scopus (786) Google Scholar,32.Bondeson D.P. et al.Catalytic in vivo protein knockdown by small-molecule PROTACs.Nat. Chem. Biol. 2015; 11: 611-617Crossref PubMed Scopus (823) Google Scholar,33.Olson C.M. et al.Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.Nat. Chem. Biol. 2018; 14: 163-170Crossref PubMed Scopus (344) Google Scholar]. Therefore, the degradation induced by PROTACs is sub-stoichiometric – one PROTAC molecule is able to induce the ubiquitination and degradation of multiple POI molecules. The catalytic nature of PROTACs provides potential strong degradation power at relatively low concentration, and it can be desirable to introduce temporal and spatial control. Recent studies have developed controllable PROTACs, such as photoswitchable azobenzene-PROTACs (Azo-PROTACs) and photo-caged PROTACs (pc-PROTACs) [34.Jin Y.H. et al.Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown.J. Med. Chem. 2020; (Published online March 19, 2020. https://doi.org/10.1021/acs.jmedchem.1029b02058)Crossref Scopus (102) Google Scholar,35.Xue G. et al.Light-induced protein degradation with photocaged PROTACs.J. Am. Chem. Soc. 2019; 141: 18370-18374Crossref PubMed Scopus (191) Google Scholar]. Azo-PROTACs are light-controlled small-molecule tools for protein knockdown in cells. The light-induced configuration change can switch to the active state to induce protein degradation, and this can be reversed by light exposure in intact cells [34.Jin Y.H. et al.Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown.J. Med. Chem. 2020; (Published online March 19, 2020. https://doi.org/10.1021/acs.jmedchem.1029b02058)Crossref Scopus (102) Google Scholar]. For pc-PROTACs, photo-removable blocking groups were added to a degrader of Brd4, and the resulting molecule showed potent degradation activity in live cells only after light irradiation [35.Xue G. et al.Light-induced protein degradation with photocaged PROTACs.J. Am. Chem. Soc. 2019; 141: 18370-18374Crossref PubMed Scopus (191) Google Scholar]. Although the PROTAC field is booming, several potential limitations have been identified: PROTAC molecules often have high molecular weight (>800 Da) and a relatively high polar surface area, likely leading to low solubility, poor cell permeability, and low oral bioavailability and blood–brain barrier penetration. The effects of PROTAC are dependent on specific E3 ligase subunits and thus are influenced by their expression, limiting their application to particular cell types. The dependence on specific E3 ligase subunits may also cause cancer cell resistance following chronic PROTAC treatment [36.Zhang L. et al.Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes.Mol. Cancer Ther. 2019; 18: 1302-1311Crossref PubMed Scopus (169) Google Scholar]. Finally, PROTAC molecules induce POI degradation via the proteasome, which has limited ability to degrade proteins with expanded repeat sequences, protein aggregates, and other non-protein molecules [37.Wong E. Cuervo A.M. Integration of clearance mechanisms: the proteasome and autophagy.Cold Spring Harb. Perspect. Biol. 2010; 2a006734Crossref PubMed Scopus (246) Google Scholar]. As discussed earlier, although the PROTAC technology is extremely promising, its dependence on the expression of specific E3 ligases and the proteasomal pathway may limit its potential applications for particular cell types or proteasome-resistant proteins. Encouragingly, novel concepts have emerged very recently regarding the lysosomal degradation pathway – a second major pathway of degradation that is independent of the proteasome [38.Tooze S.A. et al.Endocytosis and autophagy: exploitation or cooperation?.Cold Spring Harb. Perspect. Biol. 2014; 6a018358Crossref PubMed Scopus (151) Google Scholar]. The lysosomal degradation pathway includes the endosome/lysosome pathway and the autophagy pathway (reviewed in [39.Pillay C.S. et al.Endolysosomal proteolysis and its regulation.Biochem. J. 2002; 363: 417-429Crossref PubMed Scopus (282) Google Scholar,40.Kundu M. Thompson C.B. Autophagy: basic principles and relevance to disease.Annu. Rev. Pathol. 2008; 3: 427-455Crossref PubMed Scopus (474) Google Scholar]). The endosome/lysosome pathway involves sequential processing by several membrane-bound intracellular compartments: the endocytosed material is incorporated and proceeds through early endosomes, endosome carrier vesicles, late endosomes, and the lysosome for subsequent hydrolysis [39.Pillay C.S. et al.Endolysosomal proteolysis and its regulation.Biochem. J. 2002; 363: 417-429Crossref PubMed Scopus (282) Google Scholar]. The autophagy pathway starts with an isolated membrane structure called a phagophore, which is derived from lipid bilayer with lipidated LC3 proteins [41.Kabeya Y. et al.LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.EMBO J. 2000; 19: 5720-5728Crossref PubMed Scopus (5745) Google Scholar]. This phagophore expands to engulf intracellular cargoes (autophagy substrates), including proteins and other biomolecules or even organelles, thereby sequestering them in a double-membrane vesicle called the autophagosome [40.Kundu M. Thompson C.B. Autophagy: basic principles and relevance to disease.Annu. Rev. Pathol. 2008; 3: 427-455Crossref PubMed Scopus (474) Google Scholar]. The loaded autophagosome matures through fusion with the lysosome, leading to cargo degradation. Thus, both the endosome/lysosome pathway and the autophagy pathway are able to degrade target material, and new concepts have been developed to harness each of these pathways for selective degradation. The LYTAC (lysosome targeting chimera) technology is a promising strategy to exploit the endosome/lysosome pathway to degrade POIs, currently published as a preprint paper without peer review [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. Excitingly, LYTAC molecules may work on extracellular proteins as well as on membrane-bound proteins such as EGFR [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. These types of proteins are typically resistant to PROTAC, which mainly targets intracellular proteins. A LYTAC molecule consists of an antibody to a specific POI, and a 20- or 90-mer of mannose-6-phosphate (M6P) is covalently attached to this antibody. M6P is a glycan that targets proteins for degradation by binding to the cation-independent M6P receptor (CI-M6PR) [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. Thus, M6P-conjugated antibodies, namely the LYTAC molecules, are recognized by this endogenous system for lysosomal degradation of glycosylated proteins, and bring glycans together with the POI to the lysosome for degradation. In some cases the M6P-conjugated antibodies can be replaced by CI-M6PR polypeptide ligands conjugated to a small molecule that binds to the POI. The authors confirmed that a polypeptide with multiple ligands for CI-M6PR attached to biotin (a high-affinity avidin-binding molecule) targets the extracellular NeutrAvidin protein to endosomes and lysosomes [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. The advantage of the LYTAC technology is that it enables degradation of both extracellular and membrane-associated POIs, and it utilizes a ubiquitously expressed endogenous degradation pathway. The major limitation is that LYTAC molecules are relatively large, and thus lose the desired properties of small-molecule drugs. The antibody or polypeptide nature of the molecules may also induce immune responses [43.Van Regenmortel M.H. Antigenicity and immunogenicity of synthetic peptides.Biologicals. 2001; 29: 209-213Crossref PubMed Scopus (162) Google Scholar]. The LYTAC technology targets extracellular and/or membrane POIs to the endosome/lysosome pathway, and is not applicable to cytosolic proteins. However, these can be targets for autophagy, and autophagy-targeting degrader technologies are highly desirable for cytosolic POIs, especially those resistant to PROTAC molecules. Although there are several different types of autophagy, the term typically refers to macroautophagy, a multistep cellular process in which cargo proteins are engulfed into autophagosomes formed by intracellular double membranes that contain lipidated LC3 proteins [41.Kabeya Y. et al.LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.EMBO J. 2000; 19: 5720-5728Crossref PubMed Scopus (5745) Google Scholar]. Autophagy receptors such as SQSTM1/p62 may recognize Lys63 (K63) polyubiquitinated protein cargoes and shuttle them to autophagosomes for subsequent clearance [44.Kirkin V. et al.A role for ubiquitin in selective autophagy.Mol. Cell. 2009; 34: 259-269Abstract Full Text Full Text PDF PubMed Scopus (1033) Google Scholar], and this process is referred to as 'selective autophagy' [45.Johansen T. Lamark T. Selective autophagy mediated by autophagic adapter proteins.Autophagy. 2011; 7: 279-296Crossref PubMed Scopus (1377) Google Scholar,46.Filimonenko M. et al.The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy.Mol. Cell. 2010; 38: 265-279Abstract Full Text Full Text PDF PubMed Scopus (355) Google Scholar]. Two independent new degrader technologies harnessing the autophagy pathway have been reported very recently. The autophagy-targeting chimera (AUTAC) system has a similar design to the PROTAC technology [47.Takahashi D. et al.AUTACs: cargo-specific degraders using selective autophagy.Mol. Cell. 2019; 76: 797-810Abstract Full Text Full Text PDF PubMed Scopus (298) Google Scholar]. Both AUTAC and PROTAC molecules function via ubiquitination. However, instead of tethering the POIs to an E3 ligase subunit and triggering K48 polyubiquitination, AUTAC molecules trigger K63 polyubiquitination, which is recognized by the selective autophagy pathway, leading to degradation of the target POI. An AUTAC molecule contains a degradation tag (guanine derivative) and a ligand of the POI to provide target specificity. The degradation tag mimics S-guanylation, a post-translational modification of Cys-cGMP adducts formed by treatment with 8-nitro-cGMP or a similar compound [48.Sawa T. et al.Protein S-guanylation by the biological signal 8-nitroguanosine 3',5'-cyclic monophosphate.Nat. Chem. Biol. 2007; 3: 727-735Crossref PubMed Scopus (233) Google Scholar]. The authors suggest that S-guanylation is a standalone tag that marks the substrate protein for selective autophagy by inducing K63 polyubiquitination [47.Takahashi D. et al.AUTACs: cargo-specific degraders using selective autophagy.Mol. Cell. 2019; 76: 797-810Abstract Full Text Full Text PDF PubMed Scopus (298) Google Scholar]. The authors reported encouraging results that AUTAC molecules are capable of degrading POIs as well as cellular organelles such as damaged mitochondria. The design of AUTAC cleverly utilizes a process that defends cells against invading group A Streptococcus [49.Nakagawa I. et al.Autophagy defends cells against invading group A Streptococcus.Science. 2004; 306: 1037-1040Crossref PubMed Scopus (979) Google Scholar]. AUTAC molecules function through a complex multiple-step process that needs to be further clarified. In particular, the molecular mechanism mediating S-guanylation-triggered K63 ubiquitination of POIs needs to be elucidated, and the efficiency and potential off-target effects of this pathway need to be determined. This will clarify which proteins are required for the AUTAC system, how the AUTAC system is influenced by each mediator, and whether exploiting this pathway may cause changes to other cellular functions. In addition, whether AUTAC molecules influence the selective autophagy process per se and whether they are functional in vivo need to be investigated. The concept of autophagosome-tethering compound (ATTEC) illustrates a more direct strategy to harness autophagy to degrade POIs [50.Li Z. et al.ATTEC: a potential new approach to target proteinopathies.Autophagy. 2020; 16: 185-187Crossr
What problem does this paper attempt to address?
-
PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery
Shanshan Gu,Di Cui,Xiaoyu Chen,Xiufang Xiong,Yongchao Zhao
DOI: https://doi.org/10.1002/bies.201700247
2018-01-01
BioEssays
Abstract:Proteolysis-targeting chimeric molecules (PROTACs) represent an emerging technique that is receiving much attention for therapeutic intervention. The mechanism is based on the inhibition of protein function by hijacking a ubiquitin E3 ligase for protein degradation. The hetero-bifunctional PROTACs contain a ligand for recruiting an E3 ligase, a linker, and another ligand to bind with the protein targeted for degradation. Thus, PROTACs have profound potential to eliminate "undruggable" protein targets, such as transcription factors and non-enzymatic proteins, which are not limited to physiological substrates of the ubiquitin-proteasome system. These findings indicate great prospects for PROTACs in the development of therapeutics. However, there are several limitations related to poor stability, biodistribution, and penetrability in vivo. This review provides an overview of the main PROTAC-based approaches that have been developed and discusses the promising opportunities and considerations for the application of this technology in therapies and drug discovery.
-
[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]
Michèle Reboud-Ravaux
DOI: https://doi.org/10.1051/jbio/2021007
Abstract:Targeted protein degradation (TPD), discovered twenty years ago through the PROTAC technology, is rapidly developing thanks to the implication of many scientists from industry and academia. PROTAC chimeras are heterobifunctional molecules able to link simultaneously a protein to be degraded and an E3 ubiquitin ligase. This allows the protein ubiquitination and its degradation by 26S proteasome. PROTACs have evolved from small peptide molecules to small non-peptide and orally available molecules. It was shown that PROTACs are capable to degrade proteins considered as "undruggable" i.e. devoid of well-defined pockets and deep grooves possibly occupied by small molecules. Among these "hard to drug" proteins, several can be degraded by PROTACs: scaffold proteins, BAF complex, transcription factors, Ras family proteins. Two PROTACs are clinically tested for breast (ARV471) and prostate (ARV110) cancers. The protein degradation by proteasome is also induced by other types of molecules: molecular glues, hydrophobic tagging (HyT), HaloPROTACs and homo-PROTACs. Other cellular constituents are eligible to induced degradation: RNA-PROTACs for RNA binding proteins and RIBOTACs for degradation of RNA itself (SARS-CoV-2 RNA). TPD has recently moved beyond the proteasome with LYTACs (lysosome targeting chimeras) and MADTACs (macroautophagy degradation targeting chimeras). Several techniques such as screening platforms together with mathematical modeling and computational design are now used to improve the discovery of new efficient PROTACs.
-
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang,Bo Kong,Zhaohong Zhu,Fei Huang,Liliang Zhang,Tao Lu,Yadong Chen,Yanmin Zhang,Yulei Jiang
DOI: https://doi.org/10.1007/s11030-023-10606-w
2023-02-16
Molecular Diversity
Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.
chemistry, multidisciplinary, medicinal, applied
-
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
Mikihiko Naito,Nobumichi Ohoka,Norihito Shibata,Yoshinori Tsukumo
DOI: https://doi.org/10.3389/fchem.2019.00849
IF: 5.5
2019-12-10
Frontiers in Chemistry
Abstract:Technologies that induce targeted protein degradation by small molecules have been developed recently. Chimeric small molecules such as Proteolysis Targeting Chimeras (PROTACs) and Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs), and E3 modulators such as thalidomides, hijack the cellular machinery for ubiquitylation, and the ubiquitylated proteins are subjected to proteasomal degradation. This has motivated drug development in industry and academia because "undruggable targets" can now be degraded by targeted protein degradation.
chemistry, multidisciplinary
-
Key Considerations in Targeted Protein Degradation Drug Discovery and Development
Liena Qin,Han Dai,Junfeng Wang
DOI: https://doi.org/10.3389/fchem.2022.934337
IF: 5.5
2022-08-02
Frontiers in Chemistry
Abstract:Targeting proteins' enzymatic functions with small molecule inhibitors, as well as functions of receptor proteins with small-molecule agonists and antagonists, were the major forms of small-molecule drug development. These small-molecule modulators are based on a conventional occupancy-driven pharmacological approach. For proteome space traditionally considered undruggable by small-molecule modulators, such as enzymes with scaffolding functions, transcription factors, and proteins that lack well-defined binding pockets for small molecules, targeted protein degraders offer the opportunity to drug the proteome with an event-driven pharmacological approach. A degrader molecule, either PROTAC or molecular glue, brings the protein of interest (POI) and E3 ubiquitin ligase in close proximity and engages the ubiquitin-proteasome system (UPS), the cellular waste disposal system for the degradation of the POI. For the development of targeted protein degraders to meet therapeutic needs, several aspects will be considered, namely, the selective degradation of disease-causing proteins, the oral bioavailability of degraders beyond Lipinski's rule of five (bRo5) scope, demands of new E3 ubiquitin ligases and molecular glue degraders, and drug resistance of the new drug modality. This review will illustrate several under-discussed key considerations in targeted protein degradation drug discovery and development: 1) the contributing factors for the selectivity of PROTAC molecules and the design of PROTACs to selectively degrade synergistic pathological proteins; 2) assay development in combination with a multi-omics approach for the identification of new E3 ligases and their corresponding ligands, as well as molecular glue degraders; 3) a molecular design to improve the oral bioavailability of bRo5 PROTACs, and 4) drug resistance of degraders.
chemistry, multidisciplinary
-
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere,Krishnan Anand,Sumel Ashique,Jing Yang,Chongge You
DOI: https://doi.org/10.3390/molecules28104014
IF: 4.6
2023-05-11
Molecules
Abstract:A potential therapeutic strategy to treat conditions brought on by the aberrant production of a disease-causing protein is emerging for targeted protein breakdown using the PROTACs technology. Few medications now in use are tiny, component-based and utilize occupancy-driven pharmacology (MOA), which inhibits protein function for a short period of time to temporarily alter it. By utilizing an event-driven MOA, the proteolysis-targeting chimeras (PROTACs) technology introduces a revolutionary tactic. Small-molecule-based heterobifunctional PROTACs hijack the ubiquitin–proteasome system to trigger the degradation of the target protein. The main challenge PROTAC's development facing now is to find potent, tissue- and cell-specific PROTAC compounds with favorable drug-likeness and standard safety measures. The ways to increase the efficacy and selectivity of PROTACs are the main focus of this review. In this review, we have highlighted the most important discoveries related to the degradation of proteins by PROTACs, new targeted approaches to boost proteolysis' effectiveness and development, and promising future directions in medicine.
chemistry, multidisciplinary,biochemistry & molecular biology
-
Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.
Meiyang Xi,Yi Chen,Hongyu Yang,Huiting Xu,Kui Du,Chunlei Wu,Yanfei Xu,Liping Deng,Xiang Luo,Lemao Yu,Yonghua Wu,Xiaozhong Gao,Tao Cai,Bin Chen,Runpu Shen,Haopeng Sun
DOI: https://doi.org/10.1016/j.ejmech.2019.04.036
IF: 7.088
2019-01-01
European Journal of Medicinal Chemistry
Abstract:Inhibitors and nucleic acid based techniques were two main approaches to interfere with protein signaling and respective cascade in the past. Until recently, a new class of small molecules named proteolysis-targeting chimeras (PROTACs) have emerged. Each contains a target warhead, a linker and an E3 ligand. These bifunctional molecules recruit E3 ligases and target specific proteins for degradation via the ubiquitin (Ub) proteasome system (UPS). The degradation provides several advantages over inhibition in potency, selectivity and drug resistance. Thus, a variety of small molecule PROTACs have been discovered so far. In this review, we summarize the biological mechanism, advantages and recent progress of PROTACs, trying to offer an outlook in development of drugs targeting degradation in future.
-
Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins
Alexander Chan,Rebecca M Haley,Mohd Altaf Najar,David Gonzalez-Martinez,Lukasz J Bugaj,George M Burslem,Michael J Mitchell,Andrew Tsourkas
DOI: https://doi.org/10.1038/s41467-024-50235-x
2024-07-10
Abstract:Recently, targeted degradation has emerged as a powerful therapeutic modality. Relying on "event-driven" pharmacology, proteolysis targeting chimeras (PROTACs) can degrade targets and are superior to conventional inhibitors against undruggable proteins. Unfortunately, PROTAC discovery is limited by warhead scarcity and laborious optimization campaigns. To address these shortcomings, analogous protein-based heterobifunctional degraders, known as bioPROTACs, have been developed. Compared to small-molecule PROTACs, bioPROTACs have higher success rates and are subject to fewer design constraints. However, the membrane impermeability of proteins severely restricts bioPROTAC deployment as a generalized therapeutic modality. Here, we present an engineered bioPROTAC template able to complex with cationic and ionizable lipids via electrostatic interactions for cytosolic delivery. When delivered by biocompatible lipid nanoparticles, these modified bioPROTACs can rapidly degrade intracellular proteins, exhibiting near-complete elimination (up to 95% clearance) of targets within hours of treatment. Our bioPROTAC format can degrade proteins localized to various subcellular compartments including the mitochondria, nucleus, cytosol, and membrane. Moreover, substrate specificity can be easily reprogrammed, allowing modular design and targeting of clinically-relevant proteins such as Ras, Jnk, and Erk. In summary, this work introduces an inexpensive, flexible, and scalable platform for efficient intracellular degradation of proteins that may elude chemical inhibition.
-
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Meiyang Xi,Yi Chen,Hongyu Yang,Huiting Xu,Kui Du,Chunlei Wu,Yanfei Xu,Liping Deng,Xiang Luo,Lemao Yu,Yonghua Wu,Xiaozhong Gao,Tao Cai,Bin Chen,Runpu Shen,Haopeng Sun
DOI: https://doi.org/10.1016/j.ejmech.2019.04.036
IF: 7.088
2019-01-01
European Journal of Medicinal Chemistry
Abstract:Inhibitors and nucleic acid based techniques were two main approaches to interfere with protein signaling and respective cascade in the past. Until recently, a new class of small molecules named proteolysis-targeting chimeras (PROTACs) have emerged. Each contains a target warhead, a linker and an E3 ligand. These bifunctional molecules recruit E3 ligases and target specific proteins for degradation via the ubiquitin (Ub) proteasome system (UPS). The degradation provides several advantages over inhibition in potency, selectivity and drug resistance. Thus, a variety of small molecule PROTACs have been discovered so far. In this review, we summarize the biological mechanism, advantages and recent progress of PROTACs, trying to offer an outlook in development of drugs targeting degradation in future.
-
Targeted protein degradation directly engaging lysosomes or proteasomes
Jiseong Kim,Insuk Byun,Do Young Kim,Hyunhi Joh,Hak Joong Kim,Min Jae Lee
DOI: https://doi.org/10.1039/d3cs00344b
IF: 46.2
2024-02-20
Chemical Society Reviews
Abstract:Targeted protein degradation (TPD) has been established as a viable alternative to attenuate the function of a specific protein of interest in both biological and clinical contexts. The unique TPD mode-of-action has allowed previously undruggable proteins to become feasible targets, expanding the landscape of "druggable" properties and "privileged" target proteins. As TPD continues to evolve, a range of innovative strategies, which do not depend on recruiting E3 ubiquitin ligases as in proteolysis-targeting chimeras (PROTACs), have emerged. Here, we present an overview of direct lysosome- and proteasome-engaging modalities and discuss their perspectives, advantages, and limitations. We outline the chemical composition, biochemical activity, and pharmaceutical characteristics of each degrader. These alternative TPD approaches not only complement the first generation of PROTACs for intracellular protein degradation but also offer unique strategies for targeting pathologic proteins located on the cell membrane and in the extracellular space.
chemistry, multidisciplinary
-
[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]
Michèle Reboud-Ravaux
DOI: https://doi.org/10.1051/jbio/2024007
Abstract:The review is focused on recent drug discovery advances based on targeted protein degradation strategies. This new area of research has exploded leading to the development of potential drugs useful in a large variety of human diseases. They first target disease relevant proteins difficult to counteract with other classical strategies and extend now to aggregates, organelles, nucleic acids or lipidic droplets. These degraders engaged either the ubiquitin-proteasome system for PROTACs and molecular glues (first generation), or the lysosomal system via endosome-lysosome degradation (LYTACs) and autophagy-lysosome degradation (ATTEC, AUTAC, AUTOTAC) (following generations of degraders). PROTACs have expanded from the orthodox heterobifunctional ones to new derivatives such as homo-PROTACs, pro-PROTACs, CLIPTACs, HaloPROTACs, PHOTOTACs, Bac-PROTACs, AbTACs, ARN-PROTACs. The small molecular-weight molecular glues induce the formation of new ternary complexes which implicate the targeted protein and an ubiquitin ligase E3 allowing the protein ubiquinitation followed by its proteasomal degradation. Lysosomal degraders (LYTAC, ATTEC, AUTAC, AUTOTAC) specifically recognize extracellular and membrane proteins or dysfunctional organelles and transport them into lysosomes where they are degraded. They overcome the limitations observed with proteasomal degradations induced by PROTAC and molecular glues and demonstrate their potential to treat human diseases, especially neurodegenerative ones. Pharmaceutical companies are engaged at the world level to develop these new potential drugs targeting cancers, immuno-inflammatory and neurodegenerative diseases as well as a variety of other ones. Efficiency and risks for these novel therapeutic strategies are discussed.
-
Bivalent Ligands for Protein Degradation in Drug Discovery
Marcel Scheepstra,Koen F W Hekking,Luc van Hijfte,Rutger H A Folmer
DOI: https://doi.org/10.1016/j.csbj.2019.01.006
2019-01-25
Abstract:Targeting the "undruggable" proteome remains one of the big challenges in drug discovery. Recent innovations in the field of targeted protein degradation and manipulation of the ubiquitin-proteasome system open up new therapeutic approaches for disorders that cannot be targeted with conventional inhibitor paradigms. Proteolysis targeting chimeras (PROTACs) are bivalent ligands in which a compound that binds to the protein target of interest is connected to a second molecule that binds an E3 ligase via a linker. The E3 protein is usually either Cereblon or Von Hippel-Lindau. Several examples of selective PROTAC molecules with potent effect in cells and in vivo models have been reported. The degradation of specific proteins via these bivalent molecules is already allowing for the study of biochemical pathways and cell biology with more specificity than was possible with inhibitor compounds. In this review, we provide a comprehensive overview of recent developments in the field of small molecule mediated protein degradation, including transcription factors, kinases and nuclear receptors. We discuss the potential benefits of protein degradation over inhibition as well as the challenges that need to be overcome.
-
Targeted protein degradation: expanding the toolbox
Matthieu Schapira,Matthew F. Calabrese,Alex N. Bullock,Craig M. Crews
DOI: https://doi.org/10.1038/s41573-019-0047-y
IF: 112.288
2019-10-30
Nature Reviews Drug Discovery
Abstract:Proteolysis-targeting chimeras (PROTACs) and related molecules that induce targeted protein degradation by the ubiquitin–proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets. However, the technology is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated. Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degradation, and expansion of knowledge in this area is a key opportunity. Here, we briefly discuss lessons learned about targeted protein degradation in chemical biology and drug discovery and systematically review the expression profile, domain architecture and chemical tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.
pharmacology & pharmacy,biotechnology & applied microbiology
-
Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
Ming He,Wenxing Lv,Yu Rao
DOI: https://doi.org/10.3389/fcell.2021.685106
IF: 5.5
2021-06-22
Frontiers in Cell and Developmental Biology
Abstract:Proteolysis targeting chimeras (PROTAC) represents a new type of small molecule induced protein degradation technology that has emerged in recent years. PROTAC uses bifunctional small molecules to induce ubiquitination of target proteins and utilizes intracellular proteasomes for chemical knockdown. It complements the gene editing and RNA interference for protein knockdown. Compared with small molecule inhibitors, PROTAC has shown great advantages in overcoming tumor resistance, affecting the non-enzymatic function of target proteins, degrading undruggable targets, and providing new rapid and reversible chemical knockout tools. At the same time, its challenges and problems also need to be resolved as a fast-developing newchemical biology technology.
cell biology,developmental biology
-
Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins
Jiayi Lin,Jinmei Jin,Yiwen Shen,Lijun Zhang,Gang Gong,Huiting Bian,Hongzhuan Chen,Dale G. Nagle,Ye Wu,Weidong Zhang,Xin Luan
DOI: https://doi.org/10.7150/thno.62686
IF: 11.6
2021-01-01
Theranostics
Abstract:Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as "undruggable" before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.
medicine, research & experimental
-
Targeted protein degradation: mechanisms, strategies and application
Lin Zhao,Jia Zhao,Kunhong Zhong,Aiping Tong,Da Jia
DOI: https://doi.org/10.1038/s41392-022-00966-4
IF: 39.3
2022-04-04
Signal Transduction and Targeted Therapy
Abstract:Abstract Traditional drug discovery mainly focuses on direct regulation of protein activity. The development and application of protein activity modulators, particularly inhibitors, has been the mainstream in drug development. In recent years, PROteolysis TArgeting Chimeras (PROTAC) technology has emerged as one of the most promising approaches to remove specific disease-associated proteins by exploiting cells’ own destruction machinery. In addition to PROTAC, many different targeted protein degradation (TPD) strategies including, but not limited to, molecular glue, Lysosome-Targeting Chimaera (LYTAC), and Antibody-based PROTAC (AbTAC), are emerging. These technologies have not only greatly expanded the scope of TPD, but also provided fresh insights into drug discovery. Here, we summarize recent advances of major TPD technologies, discuss their potential applications, and hope to provide a prime for both biologists and chemists who are interested in this vibrant field.
biochemistry & molecular biology,cell biology
-
Targeted degradation of Pin1 by protein-destabilizing compounds
Giulia Alboreggia,Parima Udompholkul,Isaac Rodriguez,Gregor Blaha,Maurizio Pellecchia
DOI: https://doi.org/10.1073/pnas.2403330121
2024-11-14
Abstract:The concept of targeted protein degradation is at the forefront of modern drug discovery, which aims to eliminate disease-causing proteins using specific molecules. In this paper, we explored the idea to design protein degraders based on the section of ligands that cause protein destabilization, hence that facilitate the cellular breakdown of the target. Our studies present covalent agents targeting Pin1, a cis–trans prolyl isomerase that plays a crucial role in tumorigenesis. Our design strategy entailed iterative optimizations of agents for potency and Pin1 destabilization in vitro. Biophysical and cellular studies suggest that the agents may act like molecular crowbars , displacing protein-stabilizing interactions that open the structure for recognition by the proteasome degradation machinery. This approach resulted in a series of potent and effective Pin1 degraders with potential applications in target validation and in therapeutic development. We propose that our design strategy can identify molecular degraders without engineering bifunctional agents that artificially create interactions between a disease-causing protein and a ubiquitin ligase.
-
Lysosome-targeting chimaeras for degradation of extracellular proteins
Steven M. Banik,Kayvon Pedram,Simon Wisnovsky,Green Ahn,Nicholas M. Riley,Carolyn R. Bertozzi
DOI: https://doi.org/10.1038/s41586-020-2545-9
IF: 64.8
2020-07-29
Nature
Abstract:The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein—for example, enzyme inhibition or ligand blocking. However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies. Protein-degradation platforms such as proteolysis-targeting chimaeras (PROTACs)<sup><a href="/articles/s41586-020-2545-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2545-9#ref-CR2">2</a></sup> and others (for example, dTAGs<sup><a href="/articles/s41586-020-2545-9#ref-CR3">3</a></sup>, Trim-Away<sup><a href="/articles/s41586-020-2545-9#ref-CR4">4</a></sup>, chaperone-mediated autophagy targeting<sup><a href="/articles/s41586-020-2545-9#ref-CR5">5</a></sup> and SNIPERs<sup><a href="/articles/s41586-020-2545-9#ref-CR6">6</a></sup>) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degradation machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components. Extracellular and membrane-associated proteins—the products of 40% of all protein-encoding genes<sup><a href="/articles/s41586-020-2545-9#ref-CR7">7</a></sup>—are key agents in cancer, ageing-related diseases and autoimmune disorders<sup><a href="/articles/s41586-020-2545-9#ref-CR8">8</a></sup>, and so a general strategy to selectively degrade these proteins has the potential to improve human health. Here we establish the targeted degradation of extracellular and membrane-associated proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein. These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small molecule or antibody fused to chemically synthesized glycopeptide ligands that are agonists of the cation-independent mannose-6-phosphate receptor (CI-M6PR). We use LYTACs to develop a CRISPR interference screen that reveals the biochemical pathway for CI-M6PR-mediated cargo internalization in cell lines, and uncover the exocyst complex as a previously unidentified—but essential—component of this pathway. We demonstrate the scope of this platform through the degradation of therapeutically relevant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed death-ligand 1. Our results establish a modular strategy for directing secreted and membrane proteins for lysosomal degradation, with broad implications for biochemical research and for therapeutics.
multidisciplinary sciences
-
Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation
Junhyeong Yim,Junyoung Park,Gabin Kim,Ala Jo,Minseob Koh,Jongmin Park
DOI: https://doi.org/10.1002/cmdc.202400326
IF: 3.54
2024-07-13
ChemMedChem
Abstract:Proteolysis‐targeting chimeras (PROTACs) have emerged as a promising technology for inducing targeted protein degradation by leveraging the intrinsic ubiquitin‐proteasome system (UPS). While the potential druggability of PROTACs toward undruggable proteins has accelerated their rapid development and the wide‐range of applications across diverse disease contexts, off‐tissue effect and side‐effects of PROTACs have recently received attentions to improve their efficacy. To address these issues, spatial or temporal target protein degradation by PROTACs has been spotlighted. In this review, we explore chemical strategies for modulating protein degradation in a cell type‐specific (spatio‐) and time‐specific (temporal‐) manner, thereby offering insights for expanding PROTAC applications to overcome the current limitations of target protein degradation strategy.
pharmacology & pharmacy,chemistry, medicinal
-
Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective
Xiaowei Huang,Fengbo Wu,Jing Ye,Lian Wang,Xiaoyun Wang,Xiang Li,Gu He
DOI: https://doi.org/10.1016/j.apsb.2024.01.010
IF: 14.903
2024-01-01
Acta Pharmaceutica Sinica B
Abstract:Targeted protein degradation (TPD) represented by proteolysis targeting chimeras (PROTACs) marks a significant stride in drug discovery. A plethora of innovative technologies inspired by PROTAC have not only revolutionized the landscape of TPD but have the potential to unlock functionalities beyond degradation. Non-small-molecule-based approaches play an irreplaceable role in this field. A wide variety of agents spanning a broad chemical spectrum, including peptides, nucleic acids, antibodies, and even vaccines, which not only prove instrumental in overcoming the constraints of conventional small molecule entities but also provided rapidly renewing paradigms. Herein we summarize the burgeoning non-small molecule technological platforms inspired by PROTACs, including three major trajectories, to provide insights for the design strategies based on novel paradigms.